276 related articles for article (PubMed ID: 11020347)
1. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor.
Toda M; Martuza RL; Rabkin SD
Mol Ther; 2000 Oct; 2(4):324-9. PubMed ID: 11020347
[TBL] [Abstract][Full Text] [Related]
2. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.
Toda M; Martuza RL; Kojima H; Rabkin SD
J Immunol; 1998 May; 160(9):4457-64. PubMed ID: 9574551
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
4. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer.
Kim SH; Carew JF; Kooby DA; Shields J; Entwisle C; Patel S; Shah JP; Fong Y
Cancer Gene Ther; 2000 Sep; 7(9):1279-85. PubMed ID: 11023201
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells.
Armstrong CA; Botella R; Galloway TH; Murray N; Kramp JM; Song IS; Ansel JC
Cancer Res; 1996 May; 56(9):2191-8. PubMed ID: 8616871
[TBL] [Abstract][Full Text] [Related]
6. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
8. Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate vector system for gene delivery/expression of GM-CSF in human prostate cancer therapy.
Parkinson RJ; Mian S; Bishop MC; Gray T; Li G; McArdle SE; Ali S; Rees RC
Prostate; 2003 Jun; 56(1):65-73. PubMed ID: 12746848
[TBL] [Abstract][Full Text] [Related]
9. Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cell: decrease of oncogenicity and induction of protection.
Janousková O; Síma P; Kunke D
Int J Oncol; 2003 Mar; 22(3):569-77. PubMed ID: 12579310
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF.
Shi FS; Weber S; Gan J; Rakhmilevich AL; Mahvi DM
Cancer Gene Ther; 1999; 6(1):81-8. PubMed ID: 10078967
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.
Ali SA; McLean CS; Boursnell ME; Martin G; Holmes CL; Reeder S; Entwisle C; Blakeley DM; Shields JG; Todryk S; Vile R; Robins RA; Rees RC
Cancer Res; 2000 Mar; 60(6):1663-70. PubMed ID: 10749137
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice.
Cao X; Ju DW; Tao Q; Wang J; Wan T; Wang BM; Zhang W; Hamada H
Gene Ther; 1998 Aug; 5(8):1130-6. PubMed ID: 10326037
[TBL] [Abstract][Full Text] [Related]
13. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine.
Toda M; Martuza RL; Rabkin SD
Gene Ther; 2001 Feb; 8(4):332-9. PubMed ID: 11313808
[TBL] [Abstract][Full Text] [Related]
14. Experimental gene therapy against subcutaneously implanted glioma with a herpes simplex virus-defective vector expressing interferon-gamma.
Kanno H; Hattori S; Sato H; Murata H; Huang FH; Hayashi A; Suzuki N; Yamamoto I; Kawamoto S; Minami M; Miyatake S; Shuin T; Kaplitt MG
Cancer Gene Ther; 1999; 6(2):147-54. PubMed ID: 10195881
[TBL] [Abstract][Full Text] [Related]
15. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
16. Replication-defective recombinant Semliki Forest virus encoding GM-CSF as a vector system for rapid and facile generation of autologous human tumor cell vaccines.
Withoff S; Glazenburg KL; van Veen ML; Kraak MM; Hospers GA; Störkel S; de Vries EG; Wilschut J; Daemen T
Gene Ther; 2001 Oct; 8(20):1515-23. PubMed ID: 11704811
[TBL] [Abstract][Full Text] [Related]
17. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
[TBL] [Abstract][Full Text] [Related]
18. Concurrent delivery of GM-CSF and endostatin genes by a single adenoviral vector provides a synergistic effect on the treatment of orthotopic liver tumors.
Tai KF; Chen PJ; Chen DS; Hwang LH
J Gene Med; 2003 May; 5(5):386-98. PubMed ID: 12731087
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy with GM-CSF, interleukin-4 and herpes simplex virus thymidine kinase shows strong antitumor effect on lung cancer.
Park KH; Kim G; Jang SH; Kim CH; Kwon SY; Yoo CG; Kim YW; Kwon HC; Kim CM; Han SK; Shim YS; Lee CT
Anticancer Res; 2003; 23(2B):1559-64. PubMed ID: 12828142
[TBL] [Abstract][Full Text] [Related]
20. Avian adenovirus vector CELO-TK displays anticancer activity in human cancer cells and suppresses established murine melanoma tumors.
Shashkova EV; Cherenova LV; Kazansky DB; Doronin K
Cancer Gene Ther; 2005 Jul; 12(7):617-26. PubMed ID: 15761475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]